205,745 Shares in Candel Therapeutics, Inc. $CADL Acquired by Wellington Management Group LLP

Wellington Management Group LLP purchased a new position in Candel Therapeutics, Inc. (NASDAQ:CADL) during the 2nd quarter, Holdings Channel.com reports. The institutional investor purchased 205,745 shares of the company’s stock, valued at approximately $2,119,000.

A number of other institutional investors have also made changes to their positions in CADL. Invesco Ltd. bought a new stake in Candel Therapeutics in the first quarter valued at about $59,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Candel Therapeutics by 37.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 16,748 shares of the company’s stock valued at $95,000 after buying an additional 4,583 shares during the period. Rhumbline Advisers boosted its holdings in Candel Therapeutics by 26.8% during the first quarter. Rhumbline Advisers now owns 33,302 shares of the company’s stock worth $188,000 after buying an additional 7,030 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Candel Therapeutics by 31.5% during the 2nd quarter. Geode Capital Management LLC now owns 903,970 shares of the company’s stock worth $4,575,000 after buying an additional 216,509 shares during the period. Finally, JPMorgan Chase & Co. grew its position in shares of Candel Therapeutics by 36.9% during the 2nd quarter. JPMorgan Chase & Co. now owns 19,533 shares of the company’s stock worth $99,000 after buying an additional 5,270 shares during the period. 13.93% of the stock is owned by institutional investors and hedge funds.

Candel Therapeutics Price Performance

CADL stock opened at $11.33 on Friday. The stock has a 50-day moving average price of $11.14 and a two-hundred day moving average price of $8.36. The stock has a market cap of $866.97 million, a PE ratio of -8.04 and a beta of -0.48. The company has a current ratio of 16.09, a quick ratio of 16.09 and a debt-to-equity ratio of 0.38. Candel Therapeutics, Inc. has a 1 year low of $4.35 and a 1 year high of $14.00.

Candel Therapeutics (NASDAQ:CADL) last released its quarterly earnings results on Thursday, August 13th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.28). Equities analysts forecast that Candel Therapeutics, Inc. will post -1.29 EPS for the current fiscal year.

Insider Transactions at Candel Therapeutics

In other Candel Therapeutics news, insider Francesca Barone sold 23,447 shares of the business’s stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $10.06, for a total value of $235,876.82. Following the sale, the insider owned 77,362 shares in the company, valued at approximately $778,261.72. The trade was a 23.26% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CTO Seshu Tyagarajan sold 7,000 shares of the company’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $12.00, for a total value of $84,000.00. Following the transaction, the chief technology officer directly owned 76,865 shares of the company’s stock, valued at approximately $922,380. This trade represents a 8.35% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 37,447 shares of company stock valued at $390,017. 14.30% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

CADL has been the topic of a number of analyst reports. Wall Street Zen downgraded shares of Candel Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, August 16th. Weiss Ratings restated a “sell (d-)” rating on shares of Candel Therapeutics in a report on Friday, July 17th. Bank of America upped their target price on shares of Candel Therapeutics from $9.00 to $12.00 and gave the company a “neutral” rating in a research note on Friday, August 14th. HC Wainwright reissued a “buy” rating and set a $23.00 price target on shares of Candel Therapeutics in a research report on Thursday, August 13th. Finally, Zacks Research upgraded shares of Candel Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Friday, May 15th. Eight analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $19.29.

About Candel Therapeutics

Candel Therapeutics (NASDAQ:CADL) is a clinical-stage immuno-oncology company focused on the development of next-generation oncolytic viral therapies designed to treat solid tumors. The company’s lead candidate, CAN-2409, is a locally administered, gene-delivered viral therapy engineered to selectively replicate in cancer cells and induce immunogenic cell death. Candel leverages proprietary virus engineering platforms to enhance tumor-specific replication and stimulate anti-tumor immune responses, aiming to improve outcomes for patients with high unmet medical needs.

In addition to its lead program, Candel’s pipeline includes CAN-3110, an oncolytic herpes simplex virus targeting recurrent high-grade glioma, and other novel viral constructs being explored for a variety of solid tumor indications.